Amylyx Pharmaceuticals, Inc.
AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$20.17
Price-0.69%
-$0.14
1Y
Price
Market Cap
$2.243b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-59.0%
3y CAGR+359.0%
5y CAGREarnings
-$150.112m
-3.7%
1y CAGR-221.4%
3y CAGR-134.8%
5y CAGREPS
-$1.48
+3.3%
1y CAGR-221.4%
3y CAGR-135.2%
5y CAGRBook Value
$273.161m
$293.603m
Assets$20.442m
Liabilities$5.631m
DebtDebt to Assets
1.9%
-
Debt to EBITDAFree Cash Flow
-$120.528m
+2.4%
1y CAGR-547.6%
3y CAGR-384.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company